Tags

Type your tag names separated by a space and hit enter

In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Eur J Pharmacol. 2008 Apr 28; 584(2-3):297-305.EJ

Abstract

Microdialysis in intact and denervated striatum of unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats was used to investigate whether CR 3394, N-[2-(3,5-dimethyl-1-adamantyl)ethyl]acetamidine, an adamantane derivative with preferential selectivity for the NR2B subunit of the NMDA receptor, has dopamine releasing properties in vivo. We also investigated whether this NMDA antagonist can potentiate the effects of L-Dopa on extracellular dopamine in these animals. After systemic injection, there was no significant effect of CR 3394 on extracellular dopamine, at all doses studied (1, 5 and 20 mg/kg i.p.), in either intact or in denervated striatum. On the other hand, striatal perfusion with 100 microM of the compound elicited release of dopamine in intact, but not in denervated striatum. In denervated striatum of the 6-OHDA-lesioned rats, CR 3394 (5 mg/kg) significantly enhanced the dopamine release induced by L-Dopa administration (25 mg/kg i.p.) in combination with benserazide (10 mg/kg i.p.). In particular, the onset of action of L-Dopa was potentiated. However, when combined with a subthreshold dose of L-Dopa (5 mg/kg), the effects of CR 3394 were lost. We conclude that CR 3394, like other NR2B receptor antagonists, has dopamine releasing properties in vivo. It enhances the effects of suprathreshold doses of L-Dopa in the denervated striatum, but not of low doses of L-Dopa. Therefore, future studies are necessary to establish the potential of selective NR2B receptor antagonists as L-Dopa-sparing agents.

Authors+Show Affiliations

Department of Pharmaceutical Chemistry and Drug Analysis, Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Laarbeeklaan 103, B1090 Brussels, Belgium. sophie.sarre@vub.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18342306

Citation

Sarre, Sophie, et al. "In Vivo Neurochemical Effects of the NR2B Selective NMDA Receptor Antagonist CR 3394 in 6-hydroxydopamine Lesioned Rats." European Journal of Pharmacology, vol. 584, no. 2-3, 2008, pp. 297-305.
Sarre S, Lanza M, Makovec F, et al. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. Eur J Pharmacol. 2008;584(2-3):297-305.
Sarre, S., Lanza, M., Makovec, F., Artusi, R., Caselli, G., & Michotte, Y. (2008). In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. European Journal of Pharmacology, 584(2-3), 297-305. https://doi.org/10.1016/j.ejphar.2008.02.027
Sarre S, et al. In Vivo Neurochemical Effects of the NR2B Selective NMDA Receptor Antagonist CR 3394 in 6-hydroxydopamine Lesioned Rats. Eur J Pharmacol. 2008 Apr 28;584(2-3):297-305. PubMed PMID: 18342306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. AU - Sarre,Sophie, AU - Lanza,Marco, AU - Makovec,Francesco, AU - Artusi,Roberto, AU - Caselli,Gianfranco, AU - Michotte,Yvette, Y1 - 2008/02/19/ PY - 2007/10/03/received PY - 2008/02/01/revised PY - 2008/02/13/accepted PY - 2008/3/18/pubmed PY - 2008/7/2/medline PY - 2008/3/18/entrez SP - 297 EP - 305 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 584 IS - 2-3 N2 - Microdialysis in intact and denervated striatum of unilaterally 6-hydroxydopamine (6-OHDA) lesioned rats was used to investigate whether CR 3394, N-[2-(3,5-dimethyl-1-adamantyl)ethyl]acetamidine, an adamantane derivative with preferential selectivity for the NR2B subunit of the NMDA receptor, has dopamine releasing properties in vivo. We also investigated whether this NMDA antagonist can potentiate the effects of L-Dopa on extracellular dopamine in these animals. After systemic injection, there was no significant effect of CR 3394 on extracellular dopamine, at all doses studied (1, 5 and 20 mg/kg i.p.), in either intact or in denervated striatum. On the other hand, striatal perfusion with 100 microM of the compound elicited release of dopamine in intact, but not in denervated striatum. In denervated striatum of the 6-OHDA-lesioned rats, CR 3394 (5 mg/kg) significantly enhanced the dopamine release induced by L-Dopa administration (25 mg/kg i.p.) in combination with benserazide (10 mg/kg i.p.). In particular, the onset of action of L-Dopa was potentiated. However, when combined with a subthreshold dose of L-Dopa (5 mg/kg), the effects of CR 3394 were lost. We conclude that CR 3394, like other NR2B receptor antagonists, has dopamine releasing properties in vivo. It enhances the effects of suprathreshold doses of L-Dopa in the denervated striatum, but not of low doses of L-Dopa. Therefore, future studies are necessary to establish the potential of selective NR2B receptor antagonists as L-Dopa-sparing agents. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/18342306/In_vivo_neurochemical_effects_of_the_NR2B_selective_NMDA_receptor_antagonist_CR_3394_in_6_hydroxydopamine_lesioned_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(08)00178-7 DB - PRIME DP - Unbound Medicine ER -